Moreover, a recent study also reported a remarkable response (73% tumor shrinkage) in an HNSCC patient with a noncanonical activating PIK3CA mutation who received alpelisib monotherapy [83], underscoring the need to further understand the noncanonical PIK3CA mutation biology. This evidence concerns the gene PIK3CA and neoplasm.